Previous close | 237.85 |
Open | 238.38 |
Bid | 237.20 x 1100 |
Ask | 237.36 x 800 |
Day's range | 236.36 - 242.56 |
52-week range | 186.83 - 369.69 |
Volume | |
Avg. volume | 2,024,890 |
Market cap | 84.471B |
Beta (5Y monthly) | 1.29 |
PE ratio (TTM) | 62.08 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SUNNYVALE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2022. All prior year per-share information has been retroactively adjusted to reflect a three-for-one stock split that was effective as of October 4, 2021. Q2 Highlights Worldwide da Vinci procedures grew approximately 14% compared with the
Intuitive’s Ion System and Siemens Healthineers Cios Spin FDA clearance offers seamless cone beam CT scans during robotic bronchoscopy proceduresSUNNYVALE, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the U.S. Food and Drug Administration has cleared the integration of a mobile cone-beam CT (CBCT) imaging technology and the Ion Endoluminal System used for robo
SUNNYVALE, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2022. All prior year per-share information has been retroactively adjusted to reflect a three-for-one stock split. Q1 Highlights Worldwide da Vinci procedures grew approximately 19% compared with the first quarter of 2021. The first quarte